Terminated, withdrawn and suspended trials

clinicaltrialsObservedShowing 301–350 of 691 studies, most recently updated first

NCT	Title	Phase	Status	First posted	Lead sponsor	Why stopped (as posted)	Category
NCT01891695	OPSCC N0 Nodal Control With Reduced IMRT	N/A	terminated	Jul 3, 2013	Paul W. Read, MD	Study had very specific inclusion/exclusion criteria and difficult to recruit	Enrollment / accrual
NCT02295540	Hypofractionated Radiation Therapy Followed by Surgery in Treating Patients With Advanced…	N/A	withdrawn	Nov 20, 2014	Rutgers, The State University of New Jersey	slow accrual	Enrollment / accrual
NCT02408887	Total Thyroidectomy With and Without Prophylactic Central Neck Lymph Node Dissection in…	Phase 2	terminated	Apr 6, 2015	National Cancer Institute (NCI)	Slow/Insufficient accrual	Enrollment / accrual
NCT04128267	Central Pain Syndrome in Survivors of Head and Neck Cancer	N/A	terminated	Oct 16, 2019	Vanderbilt-Ingram Cancer Center	Recruitment/accrual impacted by COVID and technical issues with equipment	COVID-19 / pandemic
NCT02363647	Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic…	N/A	terminated	Feb 16, 2015	Icahn School of Medicine at Mount Sinai	No Current Funding	Funding
NCT04060342	GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With…	Phase 1	terminated	Aug 19, 2019	GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.	No clear benefit of GB1275 was observed either as monotherapy or in combination with pembrolizumab.	Other (stated, no rule matched)
NCT03862066	Memory Phenotype and PD-1 Inhibition Response in Oral Cancer	—	terminated	Mar 5, 2019	Medical University of South Carolina	Low accrual progress per internal scientific review committee	Enrollment / accrual
NCT00394147	Pemetrexed and Gemcitabine in Patients With Advanced Head and Neck Cancer	Phase 2	terminated	Oct 31, 2006	Fox Chase Cancer Center	stopped for lack of efficacy	Efficacy / futility
NCT04831450	Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC)	Phase 2	withdrawn	Apr 5, 2021	University of Miami	Investigator Decision	Investigator
NCT04001413	Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients	Phase 2	withdrawn	Jun 28, 2019	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Sponsor withdrew funding	Funding
NCT03065218	99mTc Sestamibi Scans In Thyroglobulin Positive Scan Negative Differentiated Thyroid…	Phase 4	terminated	Feb 27, 2017	Medstar Health Research Institute	Insufficient recruitment	Enrollment / accrual
NCT03720158	Enteral Omega 3 During Radiotherapy to Improve the Quality of Life and Functionality of…	N/A	terminated	Oct 25, 2018	Coordinación de Investigación en Salud, Mexico	The activities in the study hospital were seriously impacted by the medical care of COVID patients,…	COVID-19 / pandemic
NCT02325349	PET/CT Imaging of Angiogenesis in Lung or Head and Neck Cancers Prior or During…(MLAPOCHI)	Phase 2	terminated	Dec 25, 2014	Assistance Publique - Hôpitaux de Paris	Change in protocol strategy	Sponsor / business decision
NCT04596033	TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy	Phase 1	terminated	Oct 22, 2020	Genocea Biosciences, Inc.	Business reasons	Sponsor / business decision
NCT03713021	TraceIT Tissue Marker to Mark the Primary Resection Bed Margins of Oropharyngeal Cancers	N/A	terminated	Oct 19, 2018	Washington University School of Medicine	Equipment unavailable	Other (stated, no rule matched)
NCT04849377	RBD-HPV: Risk-Based De-Intensification for HPV+ HNSCC	Phase 2	withdrawn	Apr 19, 2021	Icahn School of Medicine at Mount Sinai	lack of eligible participants due to change in study criterias	Other (stated, no rule matched)
NCT00373711	Comparison of I-124 PET/CT, F-18 FDG PET/CT & I-123 Whole Body Scintigraphy for Recurrent…	—	withdrawn	Sep 8, 2006	Stanford University	Abandoned	Other (stated, no rule matched)
NCT04224792	Effects of Exercise Training on Fatigue in Thyroid Cancer Survivors	N/A	withdrawn	Jan 13, 2020	Mayo Clinic	Due to pandemic, unable to see patients	COVID-19 / pandemic
NCT03090412	Photodynamic Therapy With HPPH Compared to Standard of Care Surgery in Treating Patients…	Phase 2	terminated	Mar 24, 2017	Roswell Park Cancer Institute	low accrual	Enrollment / accrual
NCT03707860	Radiation Oncology Mobile Application(γ-App)	—	withdrawn	Oct 16, 2018	King Hussein Cancer Center	the program couldn't be implemented	Other (stated, no rule matched)
NCT04880603	Utility of Restrata With Split-thickness Skin Graft to Reconstruct the Forearm Donor Site	Phase 2	terminated	May 11, 2021	Nebraska Methodist Health System	Investigators no longer interested in pursuing	Other (stated, no rule matched)
NCT04003025	Body Composition and Prognosis in Head and Neck Squamous Cell Carcinoma (HNSCC)(HNCAX01)	—	withdrawn	Jul 1, 2019	Instituto do Cancer do Estado de São Paulo	The proposed analysis was not feasible.	Other (stated, no rule matched)
NCT04272333	Intratumoral Microdosing of Motolimod in HNSCC	Early Phase 1	terminated	Feb 17, 2020	Presage Biosciences	Partner Termination	Other (stated, no rule matched)
NCT05234606	A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1…	Phase 1 / Phase 2	withdrawn	Feb 10, 2022	Silverback Therapeutics	Sponsor decision based on strategic re-alignment	Sponsor / business decision
NCT04428047	Evaluation of Bintrafusp Alfa in Operable and Untreated Head and Neck Squamous Cell…(ICING)	Phase 2	terminated	Jun 11, 2020	UNICANCER	Sponsor decision following information on cases of hyperprogression and early toxicities with…	Safety / toxicity
NCT04266470	Monitoring Blood Flow and Metabolic Activity in Malignant Tissue of Head and Neck Region	N/A	withdrawn	Feb 12, 2020	Wake Forest University Health Sciences	Study is no longer feasible at our site.	Other (stated, no rule matched)
NCT03745690	Near-Infrared Image Guided Surgical Resection With Indocyanine Green in Treating Patients…	Phase 1 / Phase 2	withdrawn	Nov 19, 2018	Jonsson Comprehensive Cancer Center	no enrollment	Enrollment / accrual
NCT00198315	Medpulser Electroporation With Bleomycin Study to Treat Anterior Head and Neck Squamous…	Phase 3	terminated	Sep 20, 2005	Inovio Pharmaceuticals	Enrollment was stopped based on the Data Monitoring Committee's recommendation.	Enrollment / accrual
NCT04832438	9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma	Phase 2	withdrawn	Apr 5, 2021	Actuate Therapeutics Inc.	Replaced by NCT05010629	Other (stated, no rule matched)
NCT01606566	A Study to Evaluate the Safety and Efficacy of Amphinex Induced PCI of Bleomycin for…	Phase 2	terminated	May 25, 2012	PCI Biotech AS	Business reasons	Sponsor / business decision
NCT02628535	Safety Study of MGD009 in B7-H3-expressing Tumors	Phase 1	terminated	Dec 11, 2015	MacroGenics	Business decision (not for safety reasons)	Safety / toxicity
NCT04129320	Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck	Phase 2 / Phase 3	withdrawn	Oct 16, 2019	MacroGenics	Change in study design	Other (stated, no rule matched)
NCT03081897	Regional Anaesthesia and Substance P in Head and Neck Cancer(SPRANC)	N/A	suspended	Mar 16, 2017	Charite University, Berlin, Germany	for organizational reasons	Other (stated, no rule matched)
NCT00003777	Surgery, Radiation Therapy, and Combination Chemotherapy in Treating Patients With…	Phase 2	terminated	Dec 10, 2003	Abramson Cancer Center at Penn Medicine	PI left institution	Investigator
NCT05099952	Sleep and Circadian Rhythm Study in Head and Neck Cancer Patients	N/A	withdrawn	Oct 29, 2021	Roswell Park Cancer Institute	PI left institute-no accruals	Investigator
NCT02901483	A Study of PEP503 With Radiotherapy in Combination With Concurrent Chemotherapy for…	Phase 1 / Phase 2	terminated	Sep 15, 2016	PharmaEngine	bussiness reason	Other (stated, no rule matched)
NCT03937141	Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Head and Neck Cancer	Phase 2	terminated	May 3, 2019	Chinook Therapeutics, Inc. (formerly Aduro)	No substantial anti-tumor activity was observed.	Other (stated, no rule matched)
NCT03548727	Pseudo-Simultaneous Imaging of Tumor Hypoxia and Proliferation in HNC Patients Using…	Early Phase 1	withdrawn	Jun 7, 2018	Weill Medical College of Cornell University	Low Accrual	Enrollment / accrual
NCT00566540	Ph 2 Intensification Regimen for Previously Untreated, Resectable, Advanced Squamous Cell…	Phase 2	terminated	Dec 3, 2007	Ohio State University Comprehensive Cancer Center	Recruitment problems with study	Enrollment / accrual
NCT04408898	SPEARHEAD 2 Study in Subjects With Recurrent or Metastatic Head and Neck Cancer	Phase 2	withdrawn	May 29, 2020	Adaptimmune	Challenges with recruitment	Enrollment / accrual
NCT04593914	A Novel Skin Barrier Protectant for Acute Radiodermatitis(CASP-ORL)	N/A	withdrawn	Oct 20, 2020	Jessa Hospital	Covid-19	COVID-19 / pandemic
NCT02289807	Concurrent Chemotherapy in Intermediate Risk Patients Treated With Intensity-modulated…	N/A	withdrawn	Nov 13, 2014	Sun Yat-sen University	not stated	Not stated
NCT03139747	UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients…	Phase 2	suspended	May 4, 2017	Thomas Jefferson University	lack of accrual reevaluating feasibility	Enrollment / accrual
NCT04052204	Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced…	Phase 1 / Phase 2	terminated	Aug 9, 2019	Pfizer	Study prematurely terminated as the experimental treatments evaluated in study B9991040 may not…	Other (stated, no rule matched)
NCT03838692	Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer	Phase 2	withdrawn	Feb 12, 2019	Antonio Fojo	Closed by sponsor	Other (stated, no rule matched)
NCT04607642	Trial of BMX-001 or Placebo in Head and Neck Cancer Patients	Phase 2	withdrawn	Oct 29, 2020	BioMimetix JV, LLC	Will be conducted as a different study with different sponsorship	Other (stated, no rule matched)
NCT04252248	Decitabine Treatment in HPV-Induced Anogenital and Head and Neck Cancer Patients After…(DERANO)	Phase 1	terminated	Feb 5, 2020	University Hospital Heidelberg	Organizational reasons	Other (stated, no rule matched)
NCT03131206	A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid…	Phase 1 / Phase 2	terminated	Apr 27, 2017	Dana-Farber Cancer Institute	Study closed due to slow accrual and lack of efficacy.	Efficacy / futility
NCT02952586	Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC…	Phase 3	terminated	Nov 2, 2016	Pfizer	The trial prematurely terminated as recommended by the E-DMC because the boundary for futility has…	Efficacy / futility
NCT01895829	Ferumoxytol - Iron Oxide Nanoparticle Magnetic Resonance Dynamic Contrast Enhanced MRI	Early Phase 1	terminated	Jul 11, 2013	M.D. Anderson Cancer Center	Study halted prematurely and will not resume	Other (stated, no rule matched)

Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.

Data updated 23 days agoSource updated Oct 12, 2022source: clinicaltrials

Terminated, withdrawn and suspended studies

Stated reasons by category

Classification rules